Showing 7781-7790 of 8159 results for "".
- Live Cosmetic Surgery Workshop This Septemberhttps://practicaldermatology.com/news/20130812-live_cosmetic_surgery_workshop_this_september/2459480/Dr. Joe Niamtu, III will present the 2013 Ultimate Facial Rejuvenation Live Cosmetic Surgery Workshop September 20-22. The course will include lectures and live surgeries on:facelift and facial liposuction, browlift, eyelid surgery, facial implants, laser resurfacing, chemical peels, fillers, mole r
- AARS Hosting Acne and Rosacea Bootcamp September 6-8, 2013https://practicaldermatology.com/news/20130809-aars_hosting_acne_and_rosacea_bootcamp_september_6-8_2013/2459481/The American Acne and Rosacea Society (AARS) is hosting the Acne and Rosacea Bootcamp, a two-day CME event open to all medical health professionals involved in the management of acne and rosacea. The program will be held September 6-8, 2013 at the Hyatt Chicago Magnificent Mile. This event will p
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No
- LEO Launches Taclonex in Larger Package Sizehttps://practicaldermatology.com/news/20130730-leo_launches_taclonex_in_larger_package_size/2459488/LEO Pharma Inc., has launched a patient-friendly 120g package size of Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of plaque psoriasis.
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- ASDS Reports High Patient Satisfaction with Soft Tissue Filler Procedureshttps://practicaldermatology.com/news/20130729-asds_reports_high_patient_satisfaction_with_soft_tissue_filler_procedures/2459490/Dermal filler treatments are among the highest rated in consumer satisfaction, according to survey data released by the American Society for Dermatologic Surgery. The ASDS Consumer Survey on Cosmetic Dermatologic Procedures asked more than 6,300 consumers for their opinions on cosmetic treatments in
- iovera Treatment Approved in Canadahttps://practicaldermatology.com/news/20130725-iovera_treatment_approved_in_canada/2459492/ioveradegrees received regulatory approval in Canada. Developed by myoscience, inc. in California, the ioveradegrees system targets forehead wrinkles using Focused Cold TherapyTM, a technology that helps to temporarily reduce the appearance of wrinkles without leaving any toxins or chemicals behind
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP P
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.